^
Association details:
| Biomarker: | CLDN18.2 expression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | ZL-1211 (CLDN18.2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1203-ZL-1211 exhibits broad anti-tumor activity in CLDN18.2 high- and low-expressing models
Published date:
03/10/2021
Excerpt:
Here we present ZL-1211, a novel CLDN18.2-targeting monoclonal antibody that was engineered to promote enhanced ADCC and to drive efficacy in tumors that exhibit a broad range of CLDN18.2 expression levels....Consistent with our in vitro findings, ZL-1211 also exhibited greater anti-tumor efficacy than the leading clinical benchmark in CLDN18.2-positive patient-derived xenograft and syngeneic models in vivo.
